Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Drug and Alcohol Dependence|June 16, 2017
Belgian experience with direct acting antivirals in people who inject drugsRob Bielen, Christophe Moreno, Hans Van Vlierberghe, et al.
BMC Gastroenterology|February 12, 2017
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infectionStefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, et al.
Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
The International Journal on Drug Policy|June 22, 2017
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE studyHåvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
European Journal of Gastroenterology & Hepatology|January 18, 2013
Hepatitis B virus and hepatitis C virus infections in Belgium: similarities and differences in epidemics and initial managementBénédicte De Vroey, Christophe Moreno, Wim Laleman, et al.
Infectious Diseases and Therapy|June 14, 2021
Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/PibrentasvirAlessio Aghemo, Yves Horsmans, Stefan Bourgeois, et al.
The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
Pageof 4